ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,099.96
      1.02%
      US Tech 100
      17,244.80
      1.57%
      Dow Jones
      38,239.66
      0.40%
      Brent Oil
      88.165
      0.00%
      Bitcoin
      63,400.83
      -0.53%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Nektar Therapeutics (NKTR)

      7. Nektar Therapeutics (NKTR) News

      NKTR

      Nektar Therapeutics (NKTR)

      Nektar Therapeutics
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:NKTR
      DateTimeSourceHeadlineSymbolCompany
      03/22/20242:00PMPR Newswire (US)Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:NKTRNektar Therapeutics
      03/05/20245:11PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NKTRNektar Therapeutics
      03/05/20249:00AMPR Newswire (US)Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia AreataNASDAQ:NKTRNektar Therapeutics
      03/04/20244:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
      03/04/20244:15PMPR Newswire (US)Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
      03/04/20248:40AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
      03/04/20248:30AMPR Newswire (US)Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGXNASDAQ:NKTRNektar Therapeutics
      02/27/20246:00PMPR Newswire (US)Nektar Management to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:NKTRNektar Therapeutics
      02/26/20246:00PMPR Newswire (US)Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
      02/22/20248:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
      02/22/20248:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
      02/22/20248:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
      02/20/20243:55PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
      02/20/20243:51PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
      02/20/20243:50PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
      02/16/20245:16PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
      02/14/20245:03PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NKTRNektar Therapeutics
      02/14/20248:50AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NKTRNektar Therapeutics
      01/10/20244:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
      01/03/20246:00PMPR Newswire (US)Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CANASDAQ:NKTRNektar Therapeutics
      12/15/20236:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
      12/15/20236:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
      12/15/20236:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
      12/15/202312:18PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
      12/11/20236:00PMPR Newswire (US)Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:NKTRNektar Therapeutics
      11/27/20234:55PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
      11/20/20239:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
      11/20/20239:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
      11/20/20238:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
      11/17/20234:36PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
       Showing the most relevant articles for your search:NASDAQ:NKTR